Trial Profile
An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Rivipansel (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlycoMimetics
- 18 Aug 2022 Results assessing efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis from clinical study RESET (NCT02187003) and its OLE (NCT02433158) published in the Blood
- 07 Dec 2020 Post hoc analyses of the Phase 3 RESET trial and the subsequent pre-planned analysis of the OLE trial published in the GlycoMimetics Media Release.
- 07 Dec 2020 According to a GlycoMimetics media release, data from this study were presented by by University of California Davis's Theodore Wun at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.